2022
The impact of benzodiazepine exposure on treatment retention in an open-access methadone program: A retrospective cohort study
Morford K, Tetrault J, Zhou B, Li F, Gleeson B, Edelman E, Stein M, Barry D, Madden L. The impact of benzodiazepine exposure on treatment retention in an open-access methadone program: A retrospective cohort study. Drug And Alcohol Dependence 2022, 241: 109707. PMID: 36423462, PMCID: PMC9777057, DOI: 10.1016/j.drugalcdep.2022.109707.Peer-Reviewed Original ResearchConceptsBenzodiazepine exposureRetrospective cohort studyKaplan-Meier analysisTreatment retentionCohort studyCox regressionTreatment durationMedian treatment durationMultivariable Cox regressionCohort of patientsOpioid treatment programsOpioid use disorderLog-rank testSame-day accessDrug Administration recommendationsTreatment discontinuationUrine toxicologyMeier analysisMethadone programsUse disordersPatientsAdministration recommendationsTreatment entryTreatment programTreatment barriersGrief at the Heart of the Opioid Overdose Crisis: Past Lessons and Present Implications
Morford KL, Batchelor HM, Tetrault JM. Grief at the Heart of the Opioid Overdose Crisis: Past Lessons and Present Implications. Journal Of Addiction Medicine 2022, 16: 613-615. PMID: 35165230, DOI: 10.1097/adm.0000000000000976.Peer-Reviewed Original ResearchConceptsOpioid use disorderOpioid overdose crisisOverdose crisisImmunodeficiency syndrome (AIDS) epidemicCare of peopleTreatment outcomesOverdose deathsUse disordersEmotional burdenSocial support networksContext of stigmaHarmful consequencesSupport networksRole of griefGriefPatientsOverdoseCliniciansIntegration of medication for opioid use disorder training into graduate nursing education
Barcelona V, Wischik DL, Marshall A, Tetrault JM. Integration of medication for opioid use disorder training into graduate nursing education. Nursing Forum 2022, 57: 869-873. PMID: 35616353, DOI: 10.1111/nuf.12753.Peer-Reviewed Original ResearchConceptsOpioid use disorderDrug Enforcement AdministrationIntegration of medicationPrescription of medicationsGeneral medical settingsHealth care providersMore health care providersOpioid overdose crisisGraduate nursing curriculumNurse practitioner studentsRelated complicationsMedicine cliniciansCare providersX-waiverUse disordersDisorder trainingInterprofessional partnershipsNursing educationOverdose crisisPractitioner studentsAdvanced practiceMedical settingsMedicationsCOVID-19 pandemicNP studentsChapter 9 Addiction management in the outpatient setting
Shi J, Slocum B, Tetrault J, Yanagisawa K. Chapter 9 Addiction management in the outpatient setting. 2022, 169-187. DOI: 10.1016/b978-0-323-79016-1.00008-8.Peer-Reviewed Original ResearchOpioid use disorderNonmedical opioid useOpioid useUntreated opioid use disorderPain management strategiesCurrent treatment optionsOpioid overdose crisisPostoperative painOutpatient settingTreatment optionsRisk factorsGeneral practitionersHigh riskEarly deathUse disordersAddiction specialistsCurrent opioid overdose crisisMedical providersBrain physiologyInfectious diseasesAddiction managementOverdose crisisAffected individualsDisordersThoughtful approach
2021
Low Dose Initiation of Buprenorphine: A Narrative Review and Practical Approach
Cohen SM, Weimer MB, Levander XA, Peckham AM, Tetrault JM, Morford KL. Low Dose Initiation of Buprenorphine: A Narrative Review and Practical Approach. Journal Of Addiction Medicine 2021, 16: 399-406. PMID: 34954746, DOI: 10.1097/adm.0000000000000945.Peer-Reviewed Original ResearchConceptsLow dose initiationFull opioid agonistsDose initiationOpioid withdrawal symptomsOpioid agonistsBuprenorphine doseWithdrawal symptomsHigh potency synthetic opioidsOpioid use disorderAppropriate clinical situationsMu-opioid receptorsBuprenorphine initiationOpioid withdrawalStarting doseOutpatient settingCare coordinationDose changesOverdose deathsCurrent evidenceUse disordersBuprenorphineTherapeutic levelsClinical situationsSynthetic opioidsNarrative reviewPrimary care and medication management characteristics among patients receiving office-based opioid treatment with buprenorphine
Du CX, Shi J, Tetrault JM, Madden LM, Barry DT. Primary care and medication management characteristics among patients receiving office-based opioid treatment with buprenorphine. Family Practice 2021, 39: 234-240. PMID: 34893825, PMCID: PMC8947790, DOI: 10.1093/fampra/cmab166.Peer-Reviewed Original ResearchConceptsOffice-based opioid treatmentPrimary care providersOpioid use disorderUrine toxicologyOpioid treatmentMore primary care providersOutpatient primary care clinicsChronic pain statusChronic viral hepatitisPrimary care clinicsCommon comorbid conditionsPrimary care characteristicsAddiction treatment settingsHigher median numberEvidence-based treatment modelsOBOT patientsOBOT programOlder patientsPain statusViral hepatitisCommon medicationsRetrospective reviewCare clinicsChronic painComorbid conditionsTraining Medical Students, Residents, and Fellows in Opioid Use Disorder Treatment
Morford K, Falker C, Tetrault J. Training Medical Students, Residents, and Fellows in Opioid Use Disorder Treatment. 2021, 161-171. DOI: 10.1007/978-3-030-80818-1_11.Peer-Reviewed Original ResearchMedical educationCompetency-based assessmentOpioid use disorderEducational gapMedical studentsRole modelingTrainee assessmentEffective workforceCore contentEarly clinical experienceEducational interventionTraining materialsTraining levelEducationSpecific instructionsFirst-line treatment optionOpioid use disorder treatmentKey recommendationsLarge treatment gapClinical experienceOpioid-related morbidityEvidence-based treatmentsUse disorder treatmentCurriculumInstitutional strength
2020
Co-Located hepatitis C virus infection treatment within an opioid treatment program promotes opioid agonist treatment retention
Severe B, Tetrault JM, Madden L, Heimer R. Co-Located hepatitis C virus infection treatment within an opioid treatment program promotes opioid agonist treatment retention. Drug And Alcohol Dependence 2020, 213: 108116. PMID: 32599493, DOI: 10.1016/j.drugalcdep.2020.108116.Peer-Reviewed Original ResearchOpioid treatment programsOpioid use disorderOpioid agonist treatmentHCV treatmentOUD treatmentTreatment retentionHepatitis C virus infection treatmentControl groupSurvival analysisHepatitis C virus infectionTreatment programHCV care continuumC virus infectionChronic HCV infectionOutcomes of interestHCV infectionAgonist treatmentPatient retentionCare continuumVirus infectionTreatment groupsUse disordersPatientsBaseline covariatesInfection treatment
2019
Corrigendum to “Addressing discordant quantitative urine buprenorphine and norbuprenorphine levels: Case examples in opioid use disorder” [Drug Alcohol Depend. 186 (2018) 171–174]
Holt SR, Donroe JH, Cavallo DA, Tetrault JM. Corrigendum to “Addressing discordant quantitative urine buprenorphine and norbuprenorphine levels: Case examples in opioid use disorder” [Drug Alcohol Depend. 186 (2018) 171–174]. Drug And Alcohol Dependence 2019, 205: 107601. PMID: 31593815, DOI: 10.1016/j.drugalcdep.2019.107601.Peer-Reviewed Original ResearchIntegration of care for HIV and opioid use disorder
Oldfield B, Muñoz N, McGovern M, Funaro M, Villanueva M, Tetrault J, Edelman E. Integration of care for HIV and opioid use disorder. AIDS 2019, Publish Ahead of Print: &na;. PMID: 30882491, PMCID: PMC6588508, DOI: 10.1097/qad.0000000000002125.Peer-Reviewed Original ResearchConceptsHIV care settingsCare settingsClinical benefitTreatment settingsSystematic reviewBuprenorphine/naloxoneOpioid use disorderProvision of medicationsIntegration of careAntiretroviral therapyOpioid useMedication adherencePROSPERO databaseOvid MEDLINETreatment strategiesObservational studyHIVUse disordersModerate riskBehavioral interventionsScreening strategyOUDRisk reductionTreatmentUnique studies
2018
“No more falling through the cracks”: A qualitative study to inform measurement of integration of care of HIV and opioid use disorder
Oldfield BJ, Muñoz N, Boshnack N, Leavitt R, McGovern MP, Villanueva M, Tetrault JM, Edelman E. “No more falling through the cracks”: A qualitative study to inform measurement of integration of care of HIV and opioid use disorder. Journal Of Substance Use And Addiction Treatment 2018, 97: 28-40. PMID: 30577897, DOI: 10.1016/j.jsat.2018.11.007.Peer-Reviewed Original ResearchConceptsOpioid use disorderIntegration of HIVUse disordersClinical staffCare of HIVCommunity-based participatory research principlesBehavioral health integrationImproved patient outcomesEvidence-based treatmentsDiverse care settingsParticipatory research principlesPrimary carePatient outcomesPatient-centered policiesCare settingsHealth integrationHIVQualitative studyStages of changeClinic leadershipCare instrumentIntegrated carePatientsBehavioral healthMeasures of qualityOffice-Based Addiction Treatment in Primary Care Approaches That Work
Edelman EJ, Oldfield BJ, Tetrault JM. Office-Based Addiction Treatment in Primary Care Approaches That Work. Medical Clinics Of North America 2018, 102: 635-652. PMID: 29933820, DOI: 10.1016/j.mcna.2018.02.007.Peer-Reviewed Original ResearchConceptsPrimary careUse disordersPrimary care-based approachSubstance useHuman immunodeficiency virusOpioid use disorderEvidence-based treatmentsCounseling-based interventionsSubstance use disordersImmunodeficiency virusSpecialty settingsMultidisciplinary teamCare-based approachHealth disparitiesAddiction treatmentCareDisordersOptimal approachImportant settingTreatmentPharmacotherapySettingAddressing discordant quantitative urine buprenorphine and norbuprenorphine levels: Case examples in opioid use disorder
Holt SR, Donroe JH, Cavallo DA, Tetrault JM. Addressing discordant quantitative urine buprenorphine and norbuprenorphine levels: Case examples in opioid use disorder. Drug And Alcohol Dependence 2018, 186: 171-174. PMID: 29579725, DOI: 10.1016/j.drugalcdep.2017.12.040.Peer-Reviewed Original ResearchConceptsOngoing illicit drug usePatient-provider relationshipOpioid use disorderIllicit drug useUse disordersUrine adulterationTreatment planDrug useQuantitative urine testingMethadone treatment programsSubstance use disordersNorbuprenorphine levelsUrine buprenorphineUrine testingPatientsTreatment programNonjudgmental approachUrine samplesTherapeutic allianceDiscordant levelsBuprenorphineDisordersUrineNorbuprenorphineLevels
2017
Interpreting quantitative urine buprenorphine and norbuprenorphine levels in office-based clinical practice
Donroe JH, Holt SR, O’Connor P, Sukumar N, Tetrault JM. Interpreting quantitative urine buprenorphine and norbuprenorphine levels in office-based clinical practice. Drug And Alcohol Dependence 2017, 180: 46-51. PMID: 28866369, DOI: 10.1016/j.drugalcdep.2017.07.040.Peer-Reviewed Original ResearchConceptsOpioid use disorderUrine buprenorphineNorbuprenorphine levelsUrine adulterationAddiction treatment clinicsTreatment clinicsBuprenorphine medicationSublingual buprenorphineBuprenorphine treatmentTreatment cohortsRetrospective studyUrine specimenBuprenorphineUse disordersPatientsClinical practiceUrine samplesUrineClinicTreatmentMedicationsLevelsNorBUPCohortSuspicionThe Addiction Recovery Clinic
Holt SR, Segar N, Cavallo DA, Tetrault JM. The Addiction Recovery Clinic. Academic Medicine 2017, 92: 680-683. PMID: 28441678, DOI: 10.1097/acm.0000000000001480.Peer-Reviewed Original ResearchConceptsPatient satisfaction surveyInternal medicine residentsRecovery clinicSubstance useMedicine residentsUse disordersAddiction medicine specialistsOpioid use disorderOutpatient clinical servicesPrimary care practicesUnhealthy substance useSubstance use disordersAddiction treatment facilitiesSatisfaction surveyDirect referralNew patientsMedicine specialistsPatientsCare practicesPatient encountersConsecutive weeksBehavioral treatmentAddiction medicineClinical servicesVisit number
2016
Caring for patients with opioid use disorder in the hospitalCaring for patients with opioid use disorder in the hospital
Donroe JH, Holt SR, Tetrault JM. Caring for patients with opioid use disorder in the hospitalCaring for patients with opioid use disorder in the hospital. Canadian Medical Association Journal 2016, 188: cmaj.160290. PMID: 27647616, PMCID: PMC5135493, DOI: 10.1503/cmaj.160290.Peer-Reviewed Original ResearchHepatic Safety of Buprenorphine in HIV-Infected and Uninfected Patients With Opioid Use Disorder: The Role of HCV-Infection
Tetrault JM, Tate JP, Edelman EJ, Gordon AJ, Re V, Lim JK, Rimland D, Goulet J, Crystal S, Gaither JR, Gibert CL, Rodriguez-Barradas MC, Fiellin LE, Bryant K, Justice AC, Fiellin DA. Hepatic Safety of Buprenorphine in HIV-Infected and Uninfected Patients With Opioid Use Disorder: The Role of HCV-Infection. Journal Of Substance Use And Addiction Treatment 2016, 68: 62-67. PMID: 27431048, PMCID: PMC4976086, DOI: 10.1016/j.jsat.2016.06.002.Peer-Reviewed Original ResearchConceptsLiver enzyme elevationAlcohol use disorderUninfected patientsHepatotoxic medicationsHCV infectionUse disordersComposite endpointLiver injuryHIV/HCV co-infected patientsHCV co-infected patientsHIV/HCV statusPre-existing liver injuryCo-infected patientsCohort of HIVHepatitis C infectionHIV/HCVOpioid use disorderRisk of hepatotoxicityHCV statusHepatic safetyMedian ALTC infectionChart reviewEnzyme elevationHIV infection
2015
Non-Medical Prescription Opioid Use and Prescription Opioid Use Disorder: A Review.
Tetrault JM, Butner JL. Non-Medical Prescription Opioid Use and Prescription Opioid Use Disorder: A Review. The Yale Journal Of Biology And Medicine 2015, 88: 227-33. PMID: 26339205, PMCID: PMC4553642.Peer-Reviewed Original ResearchConceptsPrescription opioid use disorderOpioid use disorderNon-medical useUse disordersPrescription opioidsMedical prescription opioid usePrescription opioid useOpioid useTreatment optionsHeroin useEpidemic proportionsPotential progressionDrug useRelated stigmaMedical communityDisordersDevastating consequencesOpioidsUnited StatesReview articleUnanswered questionsNational effortsEpidemiologyProgression
2014
Substance use in older HIV-infected patients
Edelman EJ, Tetrault JM, Fiellin DA. Substance use in older HIV-infected patients. Current Opinion In HIV And AIDS 2014, 9: 317-324. PMID: 24824888, PMCID: PMC4175926, DOI: 10.1097/coh.0000000000000069.Peer-Reviewed Original ResearchConceptsOpioid use disorderUse disordersSubstance useTreatment optionsHealth consequencesPotential treatment optionStimulant use disorderRelated health consequencesOlder HIVAntiretroviral therapyHIVPatientsBrief counselingHealth outcomesEffective interventionsComplex needsMedicationsDisordersCounseling strategiesInterventionOutcomesTobaccoLife courseOptionsTherapy